Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 7:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 4,172 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Clear all
Completed Phase 3 Interventional Results available

Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer

NCT00744497
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Placebo, Dasatinib, Docetaxel, Prednisone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,930 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
43
States / cities
Mobile, Alabama • Anchorage, Alaska • Fayetteville, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 29, 2026, 7:58 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

PASCUAL (Prostate Assay Specific Clinical Utility at Launch) Study

NCT02250313
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
MDx Health
Industry
Eligibility
40 Years to 75 Years · Male only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
15
States / cities
Homewood, Alabama • San Diego, California • Torrance, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 29, 2026, 7:58 PM EDT
Completed Phase 2 Interventional Results available

Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer

NCT01023061
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
abiraterone acetate, prednisone, leuprolide acetate, laboratory biomarker analysis, external beam radiation therapy, goserelin acetate
Drug · Other · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Seattle, Washington • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 29, 2026, 7:58 PM EDT
Completed Not applicable Interventional

Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen

NCT01682941
View directory record Official record
Conditions
Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
Arm I Soy Bread, Arm II Soy-Almond Bread
Dietary Supplement
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 29, 2026, 7:58 PM EDT
Recruiting Phase 2 Interventional

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

NCT05766371
View directory record Official record
Conditions
Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Carcinoma
Interventions
Pembrolizumab, 177Lu-PSMA-617
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 29, 2026, 7:58 PM EDT
Completed Phase 2Phase 3 Interventional

Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer

NCT00004071
View directory record Official record
Conditions
Prostate Cancer
Interventions
leflunomide, mitoxantrone hydrochloride, prednisone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
3
States / cities
Boca Raton, Florida • Fort Myers, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2012 · Synced Oct 29, 2026, 7:58 PM EDT
Completed Not applicable Interventional Results available

Hypofractionated Image-Guided Radiotherapy For Prostate Cancer: The HEIGHT Trial

NCT01411332
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
SIMRT, HTIMRT
Radiation
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 85 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 29, 2026, 7:58 PM EDT
Withdrawn Not applicable Interventional

Prostatic Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH)

NCT04563221
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
Prostatic artery embolization
Device
Lead sponsor
Andrew Picel
Other
Eligibility
45 Years to 85 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 29, 2026, 7:58 PM EDT
Terminated Phase 2 Interventional

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer

NCT03360721
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Apalutamide, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 29, 2026, 7:58 PM EDT
Completed Phase 1 Interventional

Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

NCT02207504
View directory record Official record
Conditions
Castration-resistant Prostate Cancer
Interventions
Crizotinib, Enzalutamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 29, 2026, 7:58 PM EDT
Not listed Not applicable Interventional

CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer

NCT02070952
View directory record Official record
Conditions
Prostate Cancer
Interventions
CyberKnife Stereotactic Ablative Body Radiation Therapy
Radiation
Lead sponsor
Riverside Community Hospital, California
Other
Eligibility
18 Years and older · Male only
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2014 · Synced Oct 29, 2026, 7:58 PM EDT
Recruiting Phase 1 Interventional

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

NCT07090148
View directory record Official record
Conditions
Prostate Cancer Patients, Non-castrate Prostate Cancer, Recurrent Prostate Cancer, Oligometastatic Prostate Cancer (OMPC)
Interventions
pTVG-HP DNA vaccine, Anti-PD-1 monoclonal antibody
Biological · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 29, 2026, 7:58 PM EDT
Terminated No phase listed Observational

Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer

NCT02370355
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
University of Southern California
Other
Eligibility
19 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 29, 2026, 7:58 PM EDT
Not listed No phase listed Observational

Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy

NCT00133900
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer, Prostate Cancer
Interventions
Phlebotomy
Procedure
Lead sponsor
Immunicon
Industry
Eligibility
18 Years and older · Male only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2009 · Synced Oct 29, 2026, 7:58 PM EDT
Recruiting No phase listed Observational

ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials

NCT06141993
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
New York, New York • Durham, North Carolina • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 29, 2026, 7:58 PM EDT
Not listed Not applicable Interventional

Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer

NCT00770822
View directory record Official record
Conditions
Prostate Cancer
Interventions
HIFU (Sonablate® 500), Brachytherapy
Device
Lead sponsor
SonaCare Medical
Industry
Eligibility
40 Years to 75 Years · Male only
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • Naples, Florida • Myrtle Beach, South Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 29, 2026, 7:58 PM EDT
Completed Phase 2 Interventional

Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

NCT00003614
View directory record Official record
Conditions
Prostate Cancer
Interventions
estramustine phosphate sodium, paclitaxel
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
27
States / cities
Chicago, Illinois • Decatur, Illinois • Peoria, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 29, 2026, 7:58 PM EDT
Completed No phase listed Observational

Navigator Guided e-Psychoeducational Intervention

NCT02186444
View directory record Official record
Conditions
Prostate Cancer
Interventions
Personalized Health Information Navigator (PHIN), NCI Information Booklets (IB)
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 29, 2026, 7:58 PM EDT
Recruiting No phase listed Observational

Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes

NCT05898932
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Medical Management, Surgical Management
Other
Lead sponsor
Northwestern University
Other
Eligibility
50 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 29, 2026, 7:58 PM EDT
Completed Phase 2 Interventional Results available

Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer

NCT01341652
View directory record Official record
Conditions
Prostate Cancer
Interventions
pTVG-HP, rhGM-CSF
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 29, 2026, 7:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer

NCT01774071
View directory record Official record
Conditions
Prostate Cancer
Interventions
89Zr DFO-MSTP2109A
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 29, 2026, 7:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 29, 2026, 7:58 PM EDT
Completed No phase listed Observational Results available

Description of Relugolix Use in Patients With Prostate Cancer Within the VHA

NCT06462014
View directory record Official record
Conditions
Prostate Cancer
Interventions
Relugolix
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 29, 2026, 7:58 PM EDT
Terminated Phase 1 Interventional

Pilot Study of SBRT and CDX-1127 in Prostate Cancer

NCT02284971
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer
Interventions
CDX1127, SBRT
Biological · Radiation
Lead sponsor
James Larner, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 29, 2026, 7:58 PM EDT